Compare Pfizer Inc (PFE) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Pfizer Inc trades at $27.81 (market cap $158.56B), while Abrdn Physical Platinum Shares ETF trades at $15.24 (market cap $1.93B). The key difference: Pfizer Inc is far larger — about 82.2× Abrdn Physical Platinum Shares ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| PFE | PPLT | |
|---|---|---|
Market Cap | $158.56B | $1.93B |
Volume | 44,138,282 | 1,698,523 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.02 | $25.23 |
52-Week Low | $23.67 | $13.73 |
Typical Hold Time | 158 Days | 42 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.78, down 4.46% today, reflecting a bearish technical outlook with moving averages and oscillators signaling sell pressure. Recent news highlights platinum's underperformance versus other precious metals, with the term structure in contango suggesting adequate supply. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak technical signals and platinum's lag in the metals rally, though historical seasonality may offer contrarian hope. Risks include commodity price volatility and supply-demand dynamics. Investors should await updated financials for a clearer fundamental picture amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
